Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Vaccines: With Narrowed Authorization For Janssen, US FDA Catches Up To CDC

Executive Summary

Citing risk of thrombosis with thrombocytopenia syndrome, FDA restricts adenovirus-based vaccine to adults for whom other vaccines are not accessible or clinically appropriate, or who would not otherwise get a vaccine; action comes almost five months after CDC decided to preferentially favor the mRNA vaccines from Pfizer/BioNTech and Moderna.

You may also be interested in...



J&J Continues Signaling Aggressive M&A Approach To Drive Growth

Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.

ACIP Prefers mRNA COVID-19 Vaccines, But Worries Message May Not Resonate

Advisory committee says that clinical guidelines and other communications must include strong belief mRNA vaccines should be given over Janssen’s adenovirus vaccine.

With J&J’s COVID Vaccine Pause Now Lifted, The Question Is How Well The System Worked

Number of deaths and ICU admissions that may have been prevented without the pause is ‘striking,’ CDC advisory committee member says; ACIP votes to reaffirm use of J&J’s vaccine in persons 18 and older based on positive risk-benefit analysis and reports of only nine additional cases of TTS.

Topics

Related Companies

UsernamePublicRestriction

Register

PS146141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel